JP6469643B2 - 上皮幹細胞の増殖および培養のための組成物および方法 - Google Patents

上皮幹細胞の増殖および培養のための組成物および方法 Download PDF

Info

Publication number
JP6469643B2
JP6469643B2 JP2016501170A JP2016501170A JP6469643B2 JP 6469643 B2 JP6469643 B2 JP 6469643B2 JP 2016501170 A JP2016501170 A JP 2016501170A JP 2016501170 A JP2016501170 A JP 2016501170A JP 6469643 B2 JP6469643 B2 JP 6469643B2
Authority
JP
Japan
Prior art keywords
cells
cell
wnt
inhibitor
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016501170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510999A5 (enExample
JP2016510999A (ja
Inventor
カープ，ジェフリー，マイケル
イン，シアオレイ
デービッド サッチ，マーク
デービッド サッチ，マーク
ランガー，ロバート，サミュエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2016510999A publication Critical patent/JP2016510999A/ja
Publication of JP2016510999A5 publication Critical patent/JP2016510999A5/ja
Application granted granted Critical
Publication of JP6469643B2 publication Critical patent/JP6469643B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2016501170A 2013-03-14 2014-03-11 上皮幹細胞の増殖および培養のための組成物および方法 Expired - Fee Related JP6469643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783245P 2013-03-14 2013-03-14
US61/783,245 2013-03-14
PCT/US2014/023197 WO2014159356A1 (en) 2013-03-14 2014-03-11 Compositions and methods for epithelial stem cell expansion and culture

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018158354A Division JP6764909B2 (ja) 2013-03-14 2018-08-27 上皮幹細胞の増殖および培養のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2016510999A JP2016510999A (ja) 2016-04-14
JP2016510999A5 JP2016510999A5 (enExample) 2017-04-20
JP6469643B2 true JP6469643B2 (ja) 2019-02-13

Family

ID=51625153

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016501170A Expired - Fee Related JP6469643B2 (ja) 2013-03-14 2014-03-11 上皮幹細胞の増殖および培養のための組成物および方法
JP2018158354A Expired - Fee Related JP6764909B2 (ja) 2013-03-14 2018-08-27 上皮幹細胞の増殖および培養のための組成物および方法
JP2020114302A Expired - Fee Related JP6919032B2 (ja) 2013-03-14 2020-07-01 上皮幹細胞の増殖および培養のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018158354A Expired - Fee Related JP6764909B2 (ja) 2013-03-14 2018-08-27 上皮幹細胞の増殖および培養のための組成物および方法
JP2020114302A Expired - Fee Related JP6919032B2 (ja) 2013-03-14 2020-07-01 上皮幹細胞の増殖および培養のための組成物および方法

Country Status (23)

Country Link
US (4) US10041046B2 (enExample)
EP (3) EP4056677A1 (enExample)
JP (3) JP6469643B2 (enExample)
KR (1) KR102168088B1 (enExample)
CN (2) CN108865972B (enExample)
AU (1) AU2014240603B2 (enExample)
BR (1) BR112015023261A2 (enExample)
CA (2) CA3184040A1 (enExample)
CY (1) CY1122934T1 (enExample)
DK (2) DK2970890T3 (enExample)
ES (2) ES2908026T3 (enExample)
HR (1) HRP20200692T1 (enExample)
HU (2) HUE057521T2 (enExample)
IL (1) IL241572B (enExample)
LT (1) LT2970890T (enExample)
NZ (1) NZ713219A (enExample)
PL (2) PL3702443T3 (enExample)
PT (2) PT2970890T (enExample)
RS (1) RS60371B1 (enExample)
SI (1) SI2970890T1 (enExample)
SM (1) SMT202000223T1 (enExample)
WO (1) WO2014159356A1 (enExample)
ZA (1) ZA201904258B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021194153A1 (ko) * 2020-03-24 2021-09-30 한국원자력의학원 섬유화 질환 복합 치료제 개발

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509919A (ja) 2006-11-15 2010-04-02 マサチューセッツ・アイ・アンド・イア・インファーマリー 内耳細胞の生成
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
EP3061808B1 (en) 2009-02-03 2020-08-12 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3970725B1 (en) 2012-09-07 2025-08-20 Massachusetts Eye & Ear Infirmary A gamma secretase inhibitor for treating hearing loss
CN104822827B (zh) 2012-12-06 2020-01-21 干细胞生物科技公司 Lgr5+体干细胞
CA3184040A1 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor
US10597633B2 (en) 2014-05-16 2020-03-24 Koninklijke Nederlandse Akademie Van Wetenschappen Culture method for organoids
EP3149156B1 (en) 2014-05-28 2021-02-17 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
WO2016037016A1 (en) * 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
JP6804438B2 (ja) 2014-10-17 2020-12-23 チルドレンズ ホスピタル メディカル センター 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法
GB201421094D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201421092D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
US10926001B2 (en) * 2014-12-02 2021-02-23 Polarityte, Inc. Methods related to minimally polarized functional units
WO2017019850A1 (en) * 2015-07-28 2017-02-02 StemBios Technologies, Inc. Composition and method for inhibiting histone deacetylase
KR101756337B1 (ko) 2015-08-12 2017-07-10 고려대학교 산학협력단 Cxcr2 억제를 통한 인간 전분화능 줄기세포의 내배엽 및 중배엽 분화 방법
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
AU2017205194A1 (en) * 2016-01-08 2018-07-19 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
WO2017123806A1 (en) 2016-01-12 2017-07-20 Cedars-Sinai Medical Center A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
AU2017212655B2 (en) 2016-01-29 2024-01-18 Decibel Therapeutics, Inc. Expansion and differentiation of inner ear supporting cells and methods of use thereof
WO2017136462A2 (en) 2016-02-01 2017-08-10 EMULATE, Inc. Systems and methods for growth of intestinal cells in microfluidic devices
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
CN109689052A (zh) * 2016-03-02 2019-04-26 频率治疗公司 使用GSK-3-α抑制剂的受控增殖干细胞/产生内耳毛细胞的方法
US9968615B2 (en) 2016-03-02 2018-05-15 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using 3-(pyridin-2-yl)-1H-indol-2-ol based compounds
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US9913848B2 (en) 2016-03-02 2018-03-13 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using 1,2,3,4-tetrahydro-[1,4]diazepino[6,7, 1-hi]indolyl based compounds
US9913835B2 (en) 2016-03-02 2018-03-13 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using N-(alkylcarbamoyl)-1H-pyrazol-4-yl)-nicotinamide based compounds
US20190060371A1 (en) * 2016-03-02 2019-02-28 Frequency Therapeutics, Inc. Methods for controlled proliferation of vestibular stem cells / generating inner ear hair cells using wnt and tgfbeta-inhibition
US10016507B2 (en) 2016-03-02 2018-07-10 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III
EP3447126A4 (en) * 2016-04-20 2019-11-13 Kyoto Prefectural Public University Corporation METHOD FOR PRODUCING A LAYER OF CULTURED EPITHELIAL CELLS
EP4177335A1 (en) * 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
EP3690022A1 (en) * 2016-05-18 2020-08-05 Keio University Cell culture medium for culturing organoid, culture method, and organoid
CA3066107A1 (en) 2016-06-03 2017-12-07 Hough Ear Institute Combination therapies for inner ear sensory hair cell regeneration/replacement
GB201610748D0 (en) * 2016-06-20 2016-08-03 Koninklijke Nederlandse Akademie Van Wetenschappen Improved diffrentation method
EP3534976A4 (en) 2016-11-04 2020-09-16 Children's Hospital Medical Center PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE
WO2018088856A2 (ko) * 2016-11-10 2018-05-17 재단법인 아산사회복지재단 마이크로유체칩, 삼차원 채널 구조물, 이를 이용한 세포 배양 방법 및 이를 이용한 생리활성 물질의 활성평가 방법
EP3323882A1 (en) * 2016-11-18 2018-05-23 Ecole Polytechnique Fédérale de Lausanne Organoid tissue engineering
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
CN110392686A (zh) 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
US10383881B2 (en) 2016-12-30 2019-08-20 Frequency Therapeutics, Inc. 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
US11913022B2 (en) 2017-01-25 2024-02-27 Cedars-Sinai Medical Center In vitro induction of mammary-like differentiation from human pluripotent stem cells
WO2018151307A1 (ja) * 2017-02-20 2018-08-23 公立大学法人名古屋市立大学 人工多能性幹細胞由来腸管幹細胞の維持培養
US11767513B2 (en) 2017-03-14 2023-09-26 Cedars-Sinai Medical Center Neuromuscular junction
US11414648B2 (en) 2017-03-24 2022-08-16 Cedars-Sinai Medical Center Methods and compositions for production of fallopian tube epithelium
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
EP3622068B1 (en) 2017-05-10 2024-02-28 The Broad Institute, Inc. Methods for determination of mutations in single replication events
KR101966523B1 (ko) * 2017-05-29 2019-04-05 차의과학대학교 산학협력단 오가노이드 배양을 위한 조성물 및 방법
EP3630949A4 (en) * 2017-05-29 2021-03-10 Stemcell Technologies Canada Inc. COMPOSITIONS AND PROCESSES FOR OBTAINING ORGANOIDS
CN107189981B (zh) * 2017-06-07 2020-01-21 广东医科大学 Hdac6抑制剂在骨髓间充质干细胞移植中的应用
WO2019018440A1 (en) * 2017-07-17 2019-01-24 The Broad Institute, Inc. HUMAN COLON CELL ATLAS IN GOOD HEALTH AND WITH HEMORRHAGIC RECTO-COLITIS
EP3694603A4 (en) 2017-10-10 2021-07-14 Children's Hospital Medical Center ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
EP3732285A1 (en) * 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
CN108085296B (zh) * 2018-01-29 2021-04-13 清华大学 肠上皮类器官无生长因子培养方法
US12161676B2 (en) 2018-03-23 2024-12-10 Cedars-Sinai Medical Center Methods of use of islet cells
EP3775161A4 (en) 2018-04-06 2022-04-06 Cedars-Sinai Medical Center NEURODEGENERATIVE DISEASE MODELS DERIVED FROM HUMAN PLURIPOTENTIC STEM CELLS ON A MICROFLUIDIC CHIP
US11981918B2 (en) 2018-04-06 2024-05-14 Cedars-Sinai Medical Center Differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
CN110205283B (zh) * 2018-04-18 2021-04-23 浙江大学 一种诱导人羊膜上皮细胞向视网膜色素上皮细胞分化的方法及其应用
KR102099402B1 (ko) * 2018-06-28 2020-04-09 오가노이드사이언스 주식회사 타액선 줄기세포의 기능 강화용 배양 조성물 및 이를 이용한 타액선 줄기세포 기능 강화 방법
KR102887406B1 (ko) 2018-07-26 2025-11-19 칠드런즈 호스피탈 메디칼 센터 간-담도-췌장 조직 및 이를 제조하는 방법
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
US11162071B2 (en) 2018-08-17 2021-11-02 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating JAG-1
WO2020056158A1 (en) 2018-09-12 2020-03-19 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
WO2020097555A1 (en) * 2018-11-09 2020-05-14 Children's Hospital Medical Center In vitro cell culture system for producing hepatocyte-like cells and uses thereof
US20220008433A1 (en) * 2018-11-30 2022-01-13 Massachusetts Eye And Ear Infirmary Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells
CN109576225A (zh) * 2018-12-23 2019-04-05 山西医科大学 利用Rspo1抑制骨髓间充质干细胞凋亡的方法
CN109679893A (zh) * 2019-01-17 2019-04-26 浙江工商大学 基于小鼠肠道干细胞的肠上皮单层培养及表征方法
WO2020159609A1 (en) * 2019-01-30 2020-08-06 MEAD, Benjamin Elliott Small molecule enhancers of paneth cell function and differentiation
KR102050223B1 (ko) * 2019-04-04 2019-11-29 포항공과대학교 산학협력단 배아줄기세포로부터 소장 오가노이드의 제조방법
KR102334245B1 (ko) * 2019-05-29 2021-12-03 연세대학교 산학협력단 인간 미뢰 오가노이드의 배양용 조성물
WO2020247836A1 (en) * 2019-06-07 2020-12-10 Massachusetts Institute Of Technology Methods and compositions for differentiating stem cells
EP3789049A1 (en) * 2019-09-06 2021-03-10 QGel SA Method for obtaining healthy intestinal organoids
US12451250B2 (en) 2019-10-22 2025-10-21 Tempus Ai, Inc. Systems and methods for predicting therapeutic sensitivity
US11629385B2 (en) 2019-11-22 2023-04-18 Tempus Labs, Inc. Tumor organoid culture compositions, systems, and methods
JP7744340B2 (ja) 2019-12-05 2025-09-25 テンパス・エーアイ・インコーポレイテッド ハイスループット薬物スクリーニングのためのシステムおよび方法
CR20220325A (es) 2019-12-20 2022-08-19 Tenaya Therapeutics Inc Fluoroalquil-oxadiazoles y sus usos
CN111471643B (zh) * 2020-04-09 2020-12-29 创芯国际生物科技(广州)有限公司 一种通用型上呼吸道粘膜类器官的培养基及培养方法
US11561178B2 (en) 2020-04-20 2023-01-24 Tempus Labs, Inc. Artificial fluorescent image systems and methods
CN111411083B (zh) * 2020-04-22 2020-11-03 创芯国际生物科技(广州)有限公司 一种胃癌类器官的培养基及培养方法
CN111849860B (zh) * 2020-06-01 2021-12-21 浙江大学 一种利用铁元素调控肠道干细胞分化的方法及应用
CN112592896B (zh) * 2020-11-22 2024-06-25 深圳市第二人民医院(深圳市转化医学研究院) 一种肺腺癌类器官的培养液及其培养方法
JP7602932B2 (ja) * 2021-02-26 2024-12-19 株式会社マンダム 汗腺筋上皮細胞の幹細胞性維持剤、汗腺筋上皮細胞の幹細胞性を維持する方法および皮膚外用剤
IL307883A (en) 2021-04-23 2023-12-01 Tenaya Therapeutics Inc HDAC6 inhibitors for use in the treatment of dilated myocardial disease
CA3216768A1 (en) 2021-05-04 2022-11-10 Jin Yang 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
WO2022261293A1 (en) * 2021-06-09 2022-12-15 The Regents Of The University Of California Lung organoid model and method of use
KR20230073997A (ko) 2021-11-19 2023-05-26 연세대학교 산학협력단 인간 타액선 상피성 줄기세포 또는 전구세포 유래 단일클론세포 분리, 유지, 증식 및 분화 방법 및 타액선 질환 치료용 세포외소포체 생산 방법
US20250034523A1 (en) * 2021-12-09 2025-01-30 The Trustees Of Indiana University Methods of generating human cochlear hair cells
CN114480274A (zh) * 2021-12-30 2022-05-13 中国人民解放军海军军医大学第一附属医院 肠道类器官定向分化潘氏细胞的方法
CN115637251A (zh) * 2022-11-04 2023-01-24 中国人民解放军海军军医大学第一附属医院 一种诱导肠道类器官定向分化为肠吸收细胞的方法及其应用
KR102693565B1 (ko) * 2022-11-30 2024-08-08 오가노이드사이언스 주식회사 암 오가노이드 제조용 배지 조성물
CN116478912A (zh) 2023-06-07 2023-07-25 合肥工业大学 一种诱导小鼠肠道类器官定向分化为肠内分泌细胞的培养基及其应用
WO2025152110A1 (zh) * 2024-01-18 2025-07-24 五邑大学 用于阿尔兹海默症治疗的联合用药及其药物组合物
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5731144A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US6124449A (en) 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5561163A (en) 1990-08-31 1996-10-01 Deprenyl Animal Health, Inc. Treating hearing loss with deprenyl
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5837681A (en) 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6045528A (en) 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
US6806358B1 (en) 1997-12-16 2004-10-19 University Of California San Diego Peptide inhibitor of TGF-β growth factors
US6177434B1 (en) 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
CA2321307A1 (en) 1998-02-27 1999-09-02 Venkatachala L. Narayanan Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
WO2000059939A1 (en) 1999-04-05 2000-10-12 Adherex Technologies Inc. COMPOUNDS AND METHODS FOR STIMULATING β-CATENIN MEDIATED GENE EXPRESSION AND DIFFERENTIATION
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
AU783615B2 (en) 2000-05-11 2005-11-17 Consejo Superior De Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase GSK-3
US6509318B1 (en) 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
US20050287128A1 (en) 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050227936A1 (en) 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
ES2289116T3 (es) 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
US20030028905A1 (en) 2001-07-31 2003-02-06 Petra Knaus Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
CA2463822A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US20040006030A1 (en) 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of TGF-beta 2 expression
JP2005530800A (ja) 2002-05-15 2005-10-13 スミスクライン・ビーチャム・コーポレイション ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール
US20040038856A1 (en) 2002-05-17 2004-02-26 Sarvajit Chakravarty Treatment of fibroproliferative disorders using TGF-beta inhibitors
US7190468B2 (en) 2002-07-17 2007-03-13 Hewlett-Packard Development Company, L.P. Background document rendering system and method
TW200417547A (en) 2002-07-31 2004-09-16 Smithkline Beecham Corp Compounds
PL374967A1 (en) 2002-08-02 2005-11-14 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
SI1532145T1 (sl) 2002-08-02 2007-02-28 Vertex Pharma Pirazolni sestavki, koristni kot inhibitorji GSK-3
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
EP1543001B1 (en) 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer
KR20050057393A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환 성장 인자 (ｔｇｆ) 억제제로서 트리아졸 유도체
EA200500286A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
AU2003291149A1 (en) 2002-11-22 2004-06-18 Scios, Inc. USE OF TFG-Beta INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
JP2006516603A (ja) 2003-01-27 2006-07-06 ファイザー・プロダクツ・インク イソチアゾール誘導体
WO2004081009A1 (en) 2003-03-12 2004-09-23 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as tgf-beta inhibitors
EP1608631A4 (en) 2003-03-28 2008-08-20 Scios Inc BICYCLIC PYRIMIDININHIBITORS OF TGF BETA
US7314939B2 (en) 2003-06-17 2008-01-01 Millennium Pharmaceuticals, Inc. Compositions and methods for inhibiting TGF-β
GB0316756D0 (en) 2003-07-17 2003-08-20 Bp Chem Int Ltd Process
WO2005019422A2 (en) 2003-08-13 2005-03-03 The Board Of Trustees Of The University Of Illinois Silencing of tgf-beta receptor type ii expression by sirna
US7387614B2 (en) 2003-08-26 2008-06-17 University Of Maryland, Baltimore Drug delivery to the inner ear and methods of using same
JP4688680B2 (ja) 2003-10-28 2011-05-25 独立行政法人理化学研究所 ＴＧＦ−β情報伝達経路阻害剤
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
GB0327908D0 (en) 2003-12-02 2004-01-07 Neuropharma Sa GSK-3 inhibitors isolated from marine organisms
KR20070007055A (ko) 2003-12-24 2007-01-12 사이오스 인코퍼레이티드 Ｔｇｆ-베타 억제제를 이용한 악성 신경교종의 치료법
EP1723146A1 (en) 2004-03-01 2006-11-22 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
CA2568028A1 (en) 2004-05-24 2005-12-08 Auris Medical, Llc. Combined otic aspirator and medication dispenser
GB0418328D0 (en) 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
JP2007176795A (ja) 2004-08-18 2007-07-12 Univ Nihon ＴＧＦ−β遺伝子発現抑制剤
US8771754B2 (en) 2004-09-17 2014-07-08 Vanderbilt University Use of GSK3 inhibitors in combination with radiation therapies
PT3520815T (pt) 2005-02-08 2022-02-02 Genzyme Corp Anticorpos contra tgfbeta
GB0505970D0 (en) 2005-03-23 2005-04-27 Univ Edinburgh Culture medium containing kinase inhibitor, and uses thereof
ES2369282T3 (es) 2005-03-25 2011-11-29 Tibotec Pharmaceuticals Inhibidores heterobicíclicos de vhc.
WO2006105152A2 (en) 2005-03-31 2006-10-05 Stemnion, Inc. Amnion-derived cell compositions, methods of making and uses thereof
NZ564179A (en) 2005-06-30 2010-09-30 Janssen Pharmaceutica Nv Cyclic anilino - pyridinotriazines as GSK-3 inhibitors
SI1910370T1 (sl) 2005-07-22 2015-06-30 Eli Lilly And Company Piridin kinolin substituirani pirolo(1,2-b)pirazol monohidrat kot tgf-beta inhibitor
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
CN101340927A (zh) 2005-10-24 2009-01-07 西玛生物医学信息公司 TGF-β1抑制性多肽在制备免疫反应调节剂上的用途
US7951845B2 (en) 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
ITMI20060181A1 (it) 2006-02-03 2007-08-04 Univ Padova Modulatori del tgf-b e loro uso
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
US7846908B2 (en) 2006-03-16 2010-12-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of TGF-beta and therapeutic uses thereof
KR20090052884A (ko) 2006-08-23 2009-05-26 화이자 프로덕츠 인크. Ｇｓｋ-3 억제제로서의 피리미돈 화합물
JP2010509919A (ja) 2006-11-15 2010-04-02 マサチューセッツ・アイ・アンド・イア・インファーマリー 内耳細胞の生成
EP2125683B1 (en) 2006-12-19 2013-10-23 The Board of Trustees of the University of Illinois 3-benzofuranyl-4-indolyl-maleimides as potent gsk-3 inhibitors for neurodegenerative disorders
WO2009017453A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2009017455A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
EP2197876A1 (en) 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
WO2009035522A1 (en) 2007-09-14 2009-03-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
ES2690554T3 (es) 2008-03-17 2018-11-21 The Scripps Research Institute Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
WO2009142719A2 (en) 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
US20120059021A1 (en) 2008-11-11 2012-03-08 University Of Washington Compositions and methods for treating cancer and methods for predicting a response to such treatments
CA2743436C (en) 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
EP2376626A4 (en) * 2008-12-13 2012-10-17 Dna Microarray MICRO-ENVIRONMENTAL NICHE ASSAY FOR SCREENING OF INDUCED PLURIPOTENT STEM CELLS (CIPS)
WO2010075551A1 (en) 2008-12-24 2010-07-01 Massachusetts Institute Of Technology Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder
EP3061808B1 (en) * 2009-02-03 2020-08-12 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
KR101748891B1 (ko) 2009-03-11 2017-06-19 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-3 억제제로서의 7-시클로알킬아미노퀴놀론
WO2011019957A1 (en) * 2009-08-12 2011-02-17 University Of Southern California Method for formation of induced pluripotent stem cells
AU2010312240B2 (en) * 2009-10-31 2016-12-15 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
US20110135756A1 (en) 2009-12-08 2011-06-09 University Of Washington Compositions and methods for protecting sensory hair cells
CA2785233C (en) 2009-12-28 2018-10-09 Audiocure Pharma Gmbh .beta.-carbolines for treatment of hearing damages and vertigo
WO2011089416A1 (en) 2010-01-19 2011-07-28 Astrazeneca Ab Pyrazine derivatives
JP5897543B2 (ja) * 2010-03-22 2016-03-30 セルアーティス アーベー Ｗｎｔシグナル経路の調節による多能性細胞から肝細胞様細胞への分化誘導と成熟
CN103429739B (zh) 2010-05-12 2018-11-13 哥伦比亚大学纽约管理委员会 制备产生和分泌胰岛素的肠内分泌细胞的方法
KR20130101557A (ko) 2010-11-02 2013-09-13 고꾸리쯔다이가꾸호오진 구마모또 다이가꾸 장세포의 제조 방법
CA2823719A1 (en) 2011-01-24 2012-08-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for generating inner ear cells in vitro
KR101807704B1 (ko) * 2011-04-12 2017-12-13 차의과학대학교 산학협력단 역분화-증진제를 이용한 역분화 만능 줄기세포의 제조방법
EP3473099A1 (en) 2011-09-14 2019-04-24 Samumed, LLC Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
US9347042B2 (en) 2011-10-06 2016-05-24 Keio University Method for producing corneal endothelial cell
NZ630615A (en) 2012-02-24 2015-09-25 Asd Therapeutics Partners Llc Thiadiazolidinediones as gsk-3 inhibitors
US9457009B2 (en) 2012-05-31 2016-10-04 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for preventing and treating auditory dysfunctions
TW201406758A (zh) 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
GB201212960D0 (en) 2012-07-20 2012-09-05 Common Services Agency Erythroid production
JP6486272B2 (ja) 2012-09-07 2019-03-20 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞および／または支持細胞再生のための方法および組成物
WO2014050779A1 (ja) 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
PL2909204T3 (pl) 2012-10-12 2019-07-31 The Broad Institute, Inc. Inhibitory GSK3 i sposoby ich stosowania
EP2925859B1 (en) 2012-11-29 2018-05-02 Takara Bio Europe AB Maturation of hepatocyte-like cells derived from human pluripotent stem cells
US20140248696A1 (en) * 2013-03-01 2014-09-04 Wisconsin Alumni Research Foundation Methods of maintaining, expanding, and diffrentiating neuronal subtype specific progenitors
CA3184040A1 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor
WO2015168149A2 (en) 2014-04-28 2015-11-05 Massachusetts Eye & Ear Infirmary Sensorineural hair cell differentiation
US10457915B2 (en) 2014-05-15 2019-10-29 International Stem Cell Corporation Chemical differentiation of pluripotentstem cells into retinal epithelial cells
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
AU2017205194A1 (en) 2016-01-08 2018-07-19 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021194153A1 (ko) * 2020-03-24 2021-09-30 한국원자력의학원 섬유화 질환 복합 치료제 개발

Also Published As

Publication number Publication date
HUE049377T2 (hu) 2020-09-28
DK3702443T3 (da) 2022-04-04
IL241572B (en) 2020-10-29
CY1122934T1 (el) 2020-10-14
KR102168088B1 (ko) 2020-10-20
JP6764909B2 (ja) 2020-10-07
DK2970890T3 (da) 2020-05-04
PT3702443T (pt) 2022-02-17
EP3702443B1 (en) 2022-01-19
CA3184040A1 (en) 2014-10-02
RS60371B1 (sr) 2020-07-31
BR112015023261A2 (pt) 2017-07-18
LT2970890T (lt) 2020-07-10
EP2970890A4 (en) 2016-11-02
US10041047B2 (en) 2018-08-07
CN105358677B (zh) 2018-06-15
ZA201904258B (en) 2023-03-29
US20190017015A1 (en) 2019-01-17
CN108865972A (zh) 2018-11-23
ES2908026T3 (es) 2022-04-27
JP2020168015A (ja) 2020-10-15
EP2970890A1 (en) 2016-01-20
PL3702443T3 (pl) 2022-05-16
US10954490B2 (en) 2021-03-23
CA2905842A1 (en) 2014-10-02
JP6919032B2 (ja) 2021-08-11
US20210301254A1 (en) 2021-09-30
ES2786925T3 (es) 2020-10-14
EP3702443A1 (en) 2020-09-02
EP2970890B1 (en) 2020-02-12
KR20160006167A (ko) 2016-01-18
EP4056677A1 (en) 2022-09-14
CA2905842C (en) 2023-02-21
HRP20200692T1 (hr) 2020-08-07
PT2970890T (pt) 2020-04-24
HUE057521T2 (hu) 2022-05-28
HK1219754A1 (en) 2017-04-13
CN105358677A (zh) 2016-02-24
CN108865972B (zh) 2022-07-29
SI2970890T1 (sl) 2020-10-30
JP2018174947A (ja) 2018-11-15
NZ713219A (en) 2017-04-28
US20160194604A1 (en) 2016-07-07
SMT202000223T1 (it) 2020-05-08
PL2970890T3 (pl) 2020-11-16
AU2014240603B2 (en) 2017-11-09
WO2014159356A1 (en) 2014-10-02
US10041046B2 (en) 2018-08-07
US20170226477A1 (en) 2017-08-10
AU2014240603A1 (en) 2015-11-05
JP2016510999A (ja) 2016-04-14

Similar Documents

Publication Publication Date Title
JP6919032B2 (ja) 上皮幹細胞の増殖および培養のための組成物および方法
JP2021104021A (ja) 軟骨細胞系統細胞及び／又は軟骨様組織を作製するための方法及び組成物
JP2021121214A (ja) 幹細胞のための培養培地
JP2019022511A (ja) 多分化能細胞および多能性細胞の分化を方向付けることによって発生させる皮質介在ニューロンおよびその他のニューロン細胞
CN108779437A (zh) 分化的肠内分泌细胞和胰岛素产生细胞的制备
CN116234819A (zh) 胰腺内分泌细胞的分化
WO2023054396A1 (ja) 下垂体組織を含む細胞集団の製造方法及びその細胞集団
HK40034599A (en) Compositions and methods for epithelial stem cell expansion and culture
HK40034599B (en) Compositions and methods for epithelial stem cell expansion and culture
HK1260137B (en) A cell culture solution
HK1260137A1 (en) A cell culture solution
HK1219754B (en) Compositions and methods for epithelial stem cell expansion and culture
WO2024171957A1 (ja) 下垂体ホルモン産生細胞の移植

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190116

R150 Certificate of patent or registration of utility model

Ref document number: 6469643

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees